Home › NCT07226726

Patients With Congenital Myasthenic Syndrome Will be Treated With Mesenchymal Stem Cell Exosome Solution

Mesenchymal Stem Cell Exosome Treatment of Congenital Myasthenic Syndrome

Who can join

Ages 18 and older · All sexes

Inclusion Criteria:

* Patients will need a diagnosis of Congenital Myasthenic Syndrome by a licensed physician.
* Patients must be able to provide informed consent, or have a guardian who does.
* Patient must be able to travel to the site of treatment.

Exclusion Criteria:

* Patients will be excluded from the trial if they are pregnant or have active cancer (malignancy) at the screening consultation.

About the study

Patients with Congenital Myasthenic Syndrome will be treated with Mesenchymal Stem Cell Exosome solution.

What is being tested

• AlloEx exosomes (biological)

Sponsor: The Foundation for Orthopaedics and Regenerative Medicine · Participants: 20 · Started: Jan 1, 2025

Contact the study team

• Chadwick Prodromos · Phone: 18476996810

Official record on ClinicalTrials.gov — NCT07226726

Locations in the U.S.

From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.